Copyright Reports & Markets. All rights reserved.

Global Ischemia Reperfusion Injury Therapeutics Market Professional Survey Report 2019

Buy now

Table of Contents

    Executive Summary

      1 Industry Overview of Ischemia Reperfusion Injury Therapeutics

      • 1.1 Definition of Ischemia Reperfusion Injury Therapeutics
      • 1.2 Ischemia Reperfusion Injury Therapeutics Segment by Type
        • 1.2.1 Global Ischemia Reperfusion Injury Therapeutics Production Growth Rate Comparison by Types (2014-2025)
        • 1.2.2 ANV-6L15
        • 1.2.3 APP-103
        • 1.2.4 BAY-606583
        • 1.2.5 EP-80317
        • 1.2.6 GS-459679
        • 1.2.7 KN-93
        • 1.2.8 LH-021
        • 1.2.9 Others
      • 1.3 Ischemia Reperfusion Injury Therapeutics Segment by Applications
        • 1.3.1 Global Ischemia Reperfusion Injury Therapeutics Consumption Comparison by Applications (2014-2025)
        • 1.3.2 Clinic
        • 1.3.3 Hospital
        • 1.3.4 Others
      • 1.4 Global Ischemia Reperfusion Injury Therapeutics Overall Market
        • 1.4.1 Global Ischemia Reperfusion Injury Therapeutics Revenue (2014-2025)
        • 1.4.2 Global Ischemia Reperfusion Injury Therapeutics Production (2014-2025)
        • 1.4.3 North America Ischemia Reperfusion Injury Therapeutics Status and Prospect (2014-2025)
        • 1.4.4 Europe Ischemia Reperfusion Injury Therapeutics Status and Prospect (2014-2025)
        • 1.4.5 China Ischemia Reperfusion Injury Therapeutics Status and Prospect (2014-2025)
        • 1.4.6 Japan Ischemia Reperfusion Injury Therapeutics Status and Prospect (2014-2025)
        • 1.4.7 Southeast Asia Ischemia Reperfusion Injury Therapeutics Status and Prospect (2014-2025)
        • 1.4.8 India Ischemia Reperfusion Injury Therapeutics Status and Prospect (2014-2025)

      2 Manufacturing Cost Structure Analysis

      • 2.1 Raw Material and Suppliers
      • 2.2 Manufacturing Cost Structure Analysis of Ischemia Reperfusion Injury Therapeutics
      • 2.3 Manufacturing Process Analysis of Ischemia Reperfusion Injury Therapeutics
      • 2.4 Industry Chain Structure of Ischemia Reperfusion Injury Therapeutics

      3 Development and Manufacturing Plants Analysis of Ischemia Reperfusion Injury Therapeutics

      • 3.1 Capacity and Commercial Production Date
      • 3.2 Global Ischemia Reperfusion Injury Therapeutics Manufacturing Plants Distribution
      • 3.3 Major Manufacturers Technology Source and Market Position of Ischemia Reperfusion Injury Therapeutics
      • 3.4 Recent Development and Expansion Plans

      4 Key Figures of Major Manufacturers

      • 4.1 Ischemia Reperfusion Injury Therapeutics Production and Capacity Analysis
      • 4.2 Ischemia Reperfusion Injury Therapeutics Revenue Analysis
      • 4.3 Ischemia Reperfusion Injury Therapeutics Price Analysis
      • 4.4 Market Concentration Degree

      5 Ischemia Reperfusion Injury Therapeutics Regional Market Analysis

      • 5.1 Ischemia Reperfusion Injury Therapeutics Production by Regions
        • 5.1.1 Global Ischemia Reperfusion Injury Therapeutics Production by Regions
        • 5.1.2 Global Ischemia Reperfusion Injury Therapeutics Revenue by Regions
      • 5.2 Ischemia Reperfusion Injury Therapeutics Consumption by Regions
      • 5.3 North America Ischemia Reperfusion Injury Therapeutics Market Analysis
        • 5.3.1 North America Ischemia Reperfusion Injury Therapeutics Production
        • 5.3.2 North America Ischemia Reperfusion Injury Therapeutics Revenue
        • 5.3.3 Key Manufacturers in North America
        • 5.3.4 North America Ischemia Reperfusion Injury Therapeutics Import and Export
      • 5.4 Europe Ischemia Reperfusion Injury Therapeutics Market Analysis
        • 5.4.1 Europe Ischemia Reperfusion Injury Therapeutics Production
        • 5.4.2 Europe Ischemia Reperfusion Injury Therapeutics Revenue
        • 5.4.3 Key Manufacturers in Europe
        • 5.4.4 Europe Ischemia Reperfusion Injury Therapeutics Import and Export
      • 5.5 China Ischemia Reperfusion Injury Therapeutics Market Analysis
        • 5.5.1 China Ischemia Reperfusion Injury Therapeutics Production
        • 5.5.2 China Ischemia Reperfusion Injury Therapeutics Revenue
        • 5.5.3 Key Manufacturers in China
        • 5.5.4 China Ischemia Reperfusion Injury Therapeutics Import and Export
      • 5.6 Japan Ischemia Reperfusion Injury Therapeutics Market Analysis
        • 5.6.1 Japan Ischemia Reperfusion Injury Therapeutics Production
        • 5.6.2 Japan Ischemia Reperfusion Injury Therapeutics Revenue
        • 5.6.3 Key Manufacturers in Japan
        • 5.6.4 Japan Ischemia Reperfusion Injury Therapeutics Import and Export
      • 5.7 Southeast Asia Ischemia Reperfusion Injury Therapeutics Market Analysis
        • 5.7.1 Southeast Asia Ischemia Reperfusion Injury Therapeutics Production
        • 5.7.2 Southeast Asia Ischemia Reperfusion Injury Therapeutics Revenue
        • 5.7.3 Key Manufacturers in Southeast Asia
        • 5.7.4 Southeast Asia Ischemia Reperfusion Injury Therapeutics Import and Export
      • 5.8 India Ischemia Reperfusion Injury Therapeutics Market Analysis
        • 5.8.1 India Ischemia Reperfusion Injury Therapeutics Production
        • 5.8.2 India Ischemia Reperfusion Injury Therapeutics Revenue
        • 5.8.3 Key Manufacturers in India
        • 5.8.4 India Ischemia Reperfusion Injury Therapeutics Import and Export

      6 Ischemia Reperfusion Injury Therapeutics Segment Market Analysis (by Type)

      • 6.1 Global Ischemia Reperfusion Injury Therapeutics Production by Type
      • 6.2 Global Ischemia Reperfusion Injury Therapeutics Revenue by Type
      • 6.3 Ischemia Reperfusion Injury Therapeutics Price by Type

      7 Ischemia Reperfusion Injury Therapeutics Segment Market Analysis (by Application)

      • 7.1 Global Ischemia Reperfusion Injury Therapeutics Consumption by Application
      • 7.2 Global Ischemia Reperfusion Injury Therapeutics Consumption Market Share by Application (2014-2019)

      8 Ischemia Reperfusion Injury Therapeutics Major Manufacturers Analysis

      • 8.1 Nyken B.V.
        • 8.1.1 Nyken B.V. Ischemia Reperfusion Injury Therapeutics Production Sites and Area Served
        • 8.1.2 Nyken B.V. Product Introduction, Application and Specification
        • 8.1.3 Nyken B.V. Ischemia Reperfusion Injury Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.1.4 Main Business and Markets Served
      • 8.2 Omeros Corporation
        • 8.2.1 Omeros Corporation Ischemia Reperfusion Injury Therapeutics Production Sites and Area Served
        • 8.2.2 Omeros Corporation Product Introduction, Application and Specification
        • 8.2.3 Omeros Corporation Ischemia Reperfusion Injury Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.2.4 Main Business and Markets Served
      • 8.3 Opsona Therapeutics Limited
        • 8.3.1 Opsona Therapeutics Limited Ischemia Reperfusion Injury Therapeutics Production Sites and Area Served
        • 8.3.2 Opsona Therapeutics Limited Product Introduction, Application and Specification
        • 8.3.3 Opsona Therapeutics Limited Ischemia Reperfusion Injury Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.3.4 Main Business and Markets Served
      • 8.4 Orexo AB
        • 8.4.1 Orexo AB Ischemia Reperfusion Injury Therapeutics Production Sites and Area Served
        • 8.4.2 Orexo AB Product Introduction, Application and Specification
        • 8.4.3 Orexo AB Ischemia Reperfusion Injury Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.4.4 Main Business and Markets Served
      • 8.5 Pharming Group N.V.
        • 8.5.1 Pharming Group N.V. Ischemia Reperfusion Injury Therapeutics Production Sites and Area Served
        • 8.5.2 Pharming Group N.V. Product Introduction, Application and Specification
        • 8.5.3 Pharming Group N.V. Ischemia Reperfusion Injury Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.5.4 Main Business and Markets Served
      • 8.6 PledPharma AB
        • 8.6.1 PledPharma AB Ischemia Reperfusion Injury Therapeutics Production Sites and Area Served
        • 8.6.2 PledPharma AB Product Introduction, Application and Specification
        • 8.6.3 PledPharma AB Ischemia Reperfusion Injury Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.6.4 Main Business and Markets Served
      • 8.7 Prolong Pharmaceuticals
        • 8.7.1 Prolong Pharmaceuticals Ischemia Reperfusion Injury Therapeutics Production Sites and Area Served
        • 8.7.2 Prolong Pharmaceuticals Product Introduction, Application and Specification
        • 8.7.3 Prolong Pharmaceuticals Ischemia Reperfusion Injury Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.7.4 Main Business and Markets Served
      • 8.8 Proteo, Inc.
        • 8.8.1 Proteo, Inc. Ischemia Reperfusion Injury Therapeutics Production Sites and Area Served
        • 8.8.2 Proteo, Inc. Product Introduction, Application and Specification
        • 8.8.3 Proteo, Inc. Ischemia Reperfusion Injury Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.8.4 Main Business and Markets Served
      • 8.9 Prothix BV
        • 8.9.1 Prothix BV Ischemia Reperfusion Injury Therapeutics Production Sites and Area Served
        • 8.9.2 Prothix BV Product Introduction, Application and Specification
        • 8.9.3 Prothix BV Ischemia Reperfusion Injury Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.9.4 Main Business and Markets Served
      • 8.10 Stealth BioTherapeutics Inc.
        • 8.10.1 Stealth BioTherapeutics Inc. Ischemia Reperfusion Injury Therapeutics Production Sites and Area Served
        • 8.10.2 Stealth BioTherapeutics Inc. Product Introduction, Application and Specification
        • 8.10.3 Stealth BioTherapeutics Inc. Ischemia Reperfusion Injury Therapeutics Production, Revenue, Ex-factory Price and Gross Margin (2014-2019)
        • 8.10.4 Main Business and Markets Served
      • 8.11 Zealand Pharma A/S
      • 8.12 Amyndas Pharmaceuticals LLC
      • 8.13 Angion Biomedica Corp.
      • 8.14 Antipodean Pharmaceuticals, Inc.
      • 8.15 Bayer AG
      • 8.16 Biomedica Management Corporation
      • 8.17 Bolder Biotechnology, Inc.
      • 8.18 Curatis Pharma GmbH
      • 8.19 Ensemble Therapeutics Corporation
      • 8.20 Erimos Pharmaceuticals, LLC

      9 Development Trend of Analysis of Ischemia Reperfusion Injury Therapeutics Market

      • 9.1 Global Ischemia Reperfusion Injury Therapeutics Market Trend Analysis
        • 9.1.1 Global Ischemia Reperfusion Injury Therapeutics Market Size (Volume and Value) Forecast 2019-2025
      • 9.2 Ischemia Reperfusion Injury Therapeutics Regional Market Trend
        • 9.2.1 North America Ischemia Reperfusion Injury Therapeutics Forecast 2019-2025
        • 9.2.2 Europe Ischemia Reperfusion Injury Therapeutics Forecast 2019-2025
        • 9.2.3 China Ischemia Reperfusion Injury Therapeutics Forecast 2019-2025
        • 9.2.4 Japan Ischemia Reperfusion Injury Therapeutics Forecast 2019-2025
        • 9.2.5 Southeast Asia Ischemia Reperfusion Injury Therapeutics Forecast 2019-2025
        • 9.2.6 India Ischemia Reperfusion Injury Therapeutics Forecast 2019-2025
      • 9.3 Ischemia Reperfusion Injury Therapeutics Market Trend (Product Type)
      • 9.4 Ischemia Reperfusion Injury Therapeutics Market Trend (Application)
      • 10.1 Marketing Channel
        • 10.1.1 Direct Marketing
        • 10.1.2 Indirect Marketing
      • 10.3 Ischemia Reperfusion Injury Therapeutics Customers

      11 Market Dynamics

      • 11.1 Market Trends
      • 11.2 Opportunities
      • 11.3 Market Drivers
      • 11.4 Challenges
      • 11.5 Influence Factors

      12 Conclusion

        13 Appendix

        • 13.1 Methodology/Research Approach
          • 13.1.1 Research Programs/Design
          • 13.1.2 Market Size Estimation
          • 13.1.3 Market Breakdown and Data Triangulation
        • 13.2 Data Source
          • 13.2.1 Secondary Sources
          • 13.2.2 Primary Sources
        • 13.3 Author List

        The global Ischemia Reperfusion Injury Therapeutics market was valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025.
        This report focuses on Ischemia Reperfusion Injury Therapeutics volume and value at global level, regional level and company level. From a global perspective, this report represents overall Ischemia Reperfusion Injury Therapeutics market size by analyzing historical data and future prospect.
        Regionally, this report categorizes the production, apparent consumption, export and import of Ischemia Reperfusion Injury Therapeutics in North America, Europe, China, Japan, Southeast Asia and India.
        For each manufacturer covered, this report analyzes their Ischemia Reperfusion Injury Therapeutics manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

        The following manufacturers are covered:
        Nyken B.V.
        Omeros Corporation
        Opsona Therapeutics Limited
        Orexo AB
        Pharming Group N.V.
        PledPharma AB
        Prolong Pharmaceuticals
        Proteo, Inc.
        Prothix BV
        Stealth BioTherapeutics Inc.
        Zealand Pharma A/S
        Amyndas Pharmaceuticals LLC
        Angion Biomedica Corp.
        Antipodean Pharmaceuticals, Inc.
        Bayer AG
        Biomedica Management Corporation
        Bolder Biotechnology, Inc.
        Curatis Pharma GmbH
        Ensemble Therapeutics Corporation
        Erimos Pharmaceuticals, LLC

        Segment by Regions
        North America
        Europe
        China
        Japan
        Southeast Asia
        India

        Segment by Type
        ANV-6L15
        APP-103
        BAY-606583
        EP-80317
        GS-459679
        KN-93
        LH-021
        Others

        Segment by Application
        Clinic
        Hospital
        Others

        Buy now